Cargando…

Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy

The aim of the present study was to analyze copy number variations (CNV) of multiple oncogenes and tumor suppressor genes in genomic DNA from primary tumor tissue, lymph node metastasis and cell-free DNA (cfDNA) from serum of 72 urothelial carcinoma of bladder (UCB) patients treated with radical cys...

Descripción completa

Detalles Bibliográficos
Autores principales: Soave, Armin, Kluwe, Lan, Yu, Hang, Rink, Michael, Gild, Philipp, Vetterlein, Malte W., Marks, Philipp, Sauter, Guido, Fisch, Margit, Meyer, Christian P., Ludwig, Tim, Dahlem, Roland, Minner, Sarah, Pantel, Klaus, Steinbach, Bettina, Schwarzenbach, Heidi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725833/
https://www.ncbi.nlm.nih.gov/pubmed/33298978
http://dx.doi.org/10.1038/s41598-020-75869-x
_version_ 1783620785398611968
author Soave, Armin
Kluwe, Lan
Yu, Hang
Rink, Michael
Gild, Philipp
Vetterlein, Malte W.
Marks, Philipp
Sauter, Guido
Fisch, Margit
Meyer, Christian P.
Ludwig, Tim
Dahlem, Roland
Minner, Sarah
Pantel, Klaus
Steinbach, Bettina
Schwarzenbach, Heidi
author_facet Soave, Armin
Kluwe, Lan
Yu, Hang
Rink, Michael
Gild, Philipp
Vetterlein, Malte W.
Marks, Philipp
Sauter, Guido
Fisch, Margit
Meyer, Christian P.
Ludwig, Tim
Dahlem, Roland
Minner, Sarah
Pantel, Klaus
Steinbach, Bettina
Schwarzenbach, Heidi
author_sort Soave, Armin
collection PubMed
description The aim of the present study was to analyze copy number variations (CNV) of multiple oncogenes and tumor suppressor genes in genomic DNA from primary tumor tissue, lymph node metastasis and cell-free DNA (cfDNA) from serum of 72 urothelial carcinoma of bladder (UCB) patients treated with radical cystectomy (RC), using multiplex ligation-dependent probe amplification (MLPA). We hypothesized that primary tumor and lymph node metastasis show similar CNV profiles, and CNV are more present in lymph node metastasis compared to primary tumor tissue. Samples from 43 (59.7%) patients could be analyzed. In total, 35 (83%), 26 (68%) and 8 (42%) patients had CNV in primary tumor, serum and lymph node metastasis, respectively. MYC, CCND1, ERBB2 and CCNE1 displayed the most frequent amplifications. In particular, CNV in ERBB2 was associated with aggressive tumor characteristics. CNV in both ERBB2 and TOP2A were risk factors for disease recurrence. The current findings show that CNV are present in various oncogenes and tumor suppressor genes in genomic DNA from primary tumor, lymph node metastasis and cfDNA from serum. CNV were more present in genomic DNA from primary tumor tissue compared to cfDNA from serum and genomic DNA from lymph node metastasis. Patients with CNV in ERBB2 and TOP2A are at increased risk for disease recurrence following RC. Further studies are necessary to validate, whether these genes may represent promising candidates for targeted-therapy.
format Online
Article
Text
id pubmed-7725833
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-77258332020-12-14 Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy Soave, Armin Kluwe, Lan Yu, Hang Rink, Michael Gild, Philipp Vetterlein, Malte W. Marks, Philipp Sauter, Guido Fisch, Margit Meyer, Christian P. Ludwig, Tim Dahlem, Roland Minner, Sarah Pantel, Klaus Steinbach, Bettina Schwarzenbach, Heidi Sci Rep Article The aim of the present study was to analyze copy number variations (CNV) of multiple oncogenes and tumor suppressor genes in genomic DNA from primary tumor tissue, lymph node metastasis and cell-free DNA (cfDNA) from serum of 72 urothelial carcinoma of bladder (UCB) patients treated with radical cystectomy (RC), using multiplex ligation-dependent probe amplification (MLPA). We hypothesized that primary tumor and lymph node metastasis show similar CNV profiles, and CNV are more present in lymph node metastasis compared to primary tumor tissue. Samples from 43 (59.7%) patients could be analyzed. In total, 35 (83%), 26 (68%) and 8 (42%) patients had CNV in primary tumor, serum and lymph node metastasis, respectively. MYC, CCND1, ERBB2 and CCNE1 displayed the most frequent amplifications. In particular, CNV in ERBB2 was associated with aggressive tumor characteristics. CNV in both ERBB2 and TOP2A were risk factors for disease recurrence. The current findings show that CNV are present in various oncogenes and tumor suppressor genes in genomic DNA from primary tumor, lymph node metastasis and cfDNA from serum. CNV were more present in genomic DNA from primary tumor tissue compared to cfDNA from serum and genomic DNA from lymph node metastasis. Patients with CNV in ERBB2 and TOP2A are at increased risk for disease recurrence following RC. Further studies are necessary to validate, whether these genes may represent promising candidates for targeted-therapy. Nature Publishing Group UK 2020-12-09 /pmc/articles/PMC7725833/ /pubmed/33298978 http://dx.doi.org/10.1038/s41598-020-75869-x Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Soave, Armin
Kluwe, Lan
Yu, Hang
Rink, Michael
Gild, Philipp
Vetterlein, Malte W.
Marks, Philipp
Sauter, Guido
Fisch, Margit
Meyer, Christian P.
Ludwig, Tim
Dahlem, Roland
Minner, Sarah
Pantel, Klaus
Steinbach, Bettina
Schwarzenbach, Heidi
Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy
title Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy
title_full Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy
title_fullStr Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy
title_full_unstemmed Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy
title_short Copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy
title_sort copy number variations in primary tumor, serum and lymph node metastasis of bladder cancer patients treated with radical cystectomy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725833/
https://www.ncbi.nlm.nih.gov/pubmed/33298978
http://dx.doi.org/10.1038/s41598-020-75869-x
work_keys_str_mv AT soavearmin copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT kluwelan copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT yuhang copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT rinkmichael copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT gildphilipp copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT vetterleinmaltew copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT marksphilipp copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT sauterguido copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT fischmargit copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT meyerchristianp copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT ludwigtim copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT dahlemroland copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT minnersarah copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT pantelklaus copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT steinbachbettina copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy
AT schwarzenbachheidi copynumbervariationsinprimarytumorserumandlymphnodemetastasisofbladdercancerpatientstreatedwithradicalcystectomy